Key Quantitative Figures
- Approved issuance of Non-Convertible Debentures (NCDs) for an aggregate amount not exceeding INR 10,000 Crore
- NCDs to be issued in one or more tranches/series via private placement
Dates of Action
- Board Meeting Date: 12 October 2026
- Meeting Time: 5:00 PM to 5:50 PM IST
- Resignation Effective Date: 12 October 2026
- Previous Communication Date: 07 October 2026
Parties Involved
- Resigning Director: Mr. Gautam Doshi (DIN: 00004612)
- Compliance Officer: Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983)
- Legal Representative: Rashmikant and Partners (Reference No: RNP 2052 2026)
Subsidiaries Affected by Resignation
Mr. Doshi resigned from directorships and committee positions in the following Sun Pharma subsidiaries:
- Sun Pharma Laboratories Limited
- Sun Pharma Holdings, Mauritius
- Sun Pharmaceutical Industries, Inc., USA
- Taro Pharmaceuticals U.S.A., Inc., USA
Purpose and Rationale
- NCD Issuance: To raise funds through listed, rated, unsecured, redeemable non-convertible debentures
- Resignation: Due to personal reasons and commitments (as stated in resignation letter)
Governance Structure
- Finance Committee authorized to determine tranche-specific terms and conditions of NCDs
- Board approved the overall issuance framework
Confirmation Statements
- Mr. Doshi confirmed no material reasons for resignation other than personal reasons
- Resignation includes immediate cessation from all board committees of the company